n-3 AGPICL en la reversión de la esteatosis hepática: el papel de la ACOX y CAT by Tapia, G. S. et al.
GRASAS Y ACEITES 67 (2)
April–June 2016, e134
ISSN-L: 0017-3495
doi: http://dx.doi.org/10.3989/gya.0886152
n-3 LCPUFA in the reversal of hepatic steatosis: 
the role of ACOX and CAT-1
G.S. Tapia, D. González-Mañán, A. D’Espessailles and C.G. Dossi*
Molecular and Clinical Pharmacology Program, Institute of Biomedical Sciences, 
Faculty of Medicine, University of Chile, Santiago, Chile
*Corresponding author: camila.g.dossi@ug.uchile.cl
Submitted: 26 August 2015; Accepted: 22 December 2015
SUMMARY: The aim of this study was to investigate the roles of the Acyl co-enzyme A oxidase (ACOX), 
 carnitine acyl transferase I (CAT-1) and activating protein 1 (AP-1) in the reversal of hepatic steatosis with 
dietary change and n-3 long chain polyunsaturated fatty acid (n-3 LCPUFA) supplementation. Male C57BL/6J 
mice were given either a control diet (CD) or a high fat diet (HFD) for 12 weeks, and then continued with the 
CD or CD plus n-3 LCPUFA for eight weeks. After this period, body and adipose visceral tissue weight were 
analyzed and liver samples were taken to measure ACOX, CAT-1 and c-jun levels. The dietary change from 
HFD to a norm caloric diet plus n-3 LCPUFA supplementation significantly reduced liver steatosis and adipose 
tissue: body weight ratio, along with an increase in the hepatic ACOX and CAT-1 levels and normalization 
of AP-1 expression that could favor the fatty acid beta-oxidation over lipogenesis and regulate inflammation. 
These results provide new data on the enzymatic metabolism underlying dietary change to a norm caloric diet 
plus n-3 LCPUFA supplementation.
KEYWORDS: ACOX (Acyl coenzyme A oxidase); AP-1(activating protein 1); CAT-1 (carnitine acyl transferase I); 
HFD (high fat diet); NAFLD (non-alcoholic fatty liver disease); n-3 LCPUFA (n-3 long chain polyunsaturated fatty 
acid); Reversion
RESUMEN: n-3 AGPICL en la reversión de la esteatosis hepática: el papel de la ACOX y CAT. El objetivo de 
este estudio fue investigar el rol de las enzimas Acil coenzima A oxidasa (ACOX) y Acil carnitina  transferasa 
1  (CAT-1), además del factor de transcripción, Proteína activadora 1 (AP-1) en la reversión de la esteatosis 
 hepática mediante cambio de dieta más suplementación con Ácidos grasos poliinsaturados de cadena larga 
omega tres (AGPICL n-3). Ratones macho de la cepa C57BL/6J fueron alimentados con dieta control (DC) o 
alta en grasas (DAG) durante 12 semanas, luego continuaron con DC con o sin suplementación de AGPICL 
n-3 durante 8 semanas. Después de este período, se analizó el peso corporal y del tejido adiposo visceral; 
en las muestras hepáticas se evaluaron los niveles de ACOX, CAT-1 y AP-1. El cambio a dieta control más 
suplementación con AGPICL n-3 reduce significativamente la esteatosis hepática y la relación tejido adiposo/
peso corporal, acompañado de un incremento en los niveles hepáticos de ACOX y CAT-1 y normalización de 
la expresión de AP-1; regulando la inflamación y favoreciendo la beta-oxidación sobre la lipogénesis. Estos 
 resultados proveen nuevos datos sobre el metabolismo enzimático cuando se realiza cambio a dieta control más 
suplementación con AGPICL n-3.
PALABRAS CLAVE: ACOX (Acil coenzima A oxidasa); AGPICL n-3 (ácidos grasos poliinsaturados de cadena 
larga omega tres); AP-1 (Proteína activadora 1); CAT-1 (Acil carnitina transferasa 1); DAG (dieta alta en grasa); 
Enfermedad del hígado graso no alcohólico (EHGNA); Esteatosis hepática; Reversión
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1. INTRODUCTION
The non-alcoholic fatty liver disease (NAFLD) 
is considered to be the hepatic expression of the 
 metabolic syndrome, defined as the clustering of 
risk factors for cardiovascular disease and type II 
diabetes, which include hyperglycemia, insulin resis-
tance, hypertriglyceridemia and obesity (Bellentani 
et al., 2009; Malaguarnera et al., 2009). It is the most 
prominent cause of chronic liver disease and it is 
characterized by a intra-hepatic triacylglycerol (TG) 
content higher than 5% of the liver weight (steatosis) 
in the absence of significant alcohol consumption 
(10–20g/day in women; 20–30 g/day in men) (Musso 
et  al., 2009), which can progress to inflammation 
(steatohepatitis), fibrosis, and cirrhosis (Valenzuela 
et al., 2011). The pathogenic mechanisms involved 
in the development of hepatic steatosis are not com-
pletely understood, but it is known that it results 
from an imbalance between lipid availability, either 
from enhanced uptake and/or de novo lipogenesis, 
and lipid disposal, either from decreased mitochon-
drial and peroxisomal fatty acid oxidation and/
or reduced lipid output by the liver (Musso et al., 
2009). The establishment of liver steatosis leads to 
the production of free radicals with a lipid peroxi-
dation response, pro-inflammatory cytokine release 
(Aronis et  al., 2005), and n-3 long-chain polyun-
saturated fatty acid (n-3 LCPUFA) depletion, with 
enhancement in the n-6/n-3 LCPUFA ratio favoring 
a pro-inflammatory state. This n-3 LCPUFA deple-
tion induces changes in the DNA binding activity of 
the peroxisome proliferator-activated receptor Alfa 
(PPAR-α) (Valenzuela et al., 2011), with a decrease 
in PPAR-α phosphorylation thus eliciting low tran-
scription levels of the target genes for carnitine acyl 
transferase 1 (CAT-1) and acyl coenzyme A oxidase 
(ACOX), favoring lipogenesis over fatty acid oxida-
tion (Araya et al., 2004; Araya et al., 2010). CAT-1 
is an enzyme that regulates the process of beta 
 oxidation in mitochondria, while ACOX is respon-
sible for fatty acid dehydrogenation to promote the 
beta oxidation process in the peroxisomes (Barlett 
et al., 2004; Poirier et al., 2006).
Secondly, it has been shown that in NAFLD the 
DNA binding of c-jun (AP-1 subunit) is increased, 
enhancing the production of pro-inflammatory 
cytokines, which promote an inflammation state 
and facilitate the development and progression of 
the disease (Dorn et al., 2014).
The transcriptional factor AP-1 is a protein 
 complex of two subunits from families Jun (c-jun, 
junB and junD) and Fos (c-Fos, FosB, among  others) 
forming homo-dimers or hetero-dimers between 
them (Halazonetti et  al., 1988). AP-1 is capable of 
promoting cytokine expressions such as TNF-α 
(tumor necrosis Alfa factor), IL (interleukin)-1 and 
2: which are involved in the recruitment and activa-
tion of Kupffer cells and the progression of NAFLD 
(Baffy, 2009).
Because of the increasing prevalence of NAFLD, 
numerous studies have focused on therapeutic 
 strategies for this liver disease which have included 
weight loss, physical activity, and therapies based 
on insulin sensitizers, lipid-lowering agents, antioxi-
dant drugs and n-3 LCPUFAs (Nobili et al., 2012).
Previous studies by our group have demonstrated 
that n-3 LCPUFA supplementation prevents the pro-
steatotic and pro-inflammatory effects of a high-fat 
diet (HFD) at the hepatic level (Valenzuela et  al., 
2012). Furthermore, the dietary change from HFD 
to a norm caloric diet with n-3 LCPUFA supplemen-
tation significantly reduced insulin resistance and 
liver steatosis when compared to switching HFD to a 
norm caloric diet alone (Dossi et al., 2014).
The aim of this study was to investigate the role of 
ACOX, CAT-1 and AP-1 in the reversal of hepatic 
steatosis with dietary change and n-3 LCPUFA 
supplementation. Parameters related to liver mor-
phological characteristics (lipid vesicles), metabolic 
syndrome (visceral adipose tissue), liver total fat 
content, enzymes involved in lipid  metabolism as 
ACOX and CAT-1 (western blot and PCR), and 
the levels of the AP-1 c-jun subunit (immunohisto-
chemistry) were determined.
2. MATERIALS AND METHODS
2.1. Ethics statement
Experimental animal protocols and animal 
 procedures complied with the Guide for the Care 
and Use of Laboratory Animals (National Academy 
of Sciences, NIH Publication 6–23, revised 1985) 
and were approved by the Bioethics Committee 
for Research in Animals, Faculty of Medicine, 
University of Chile (CBA 0386 FMUCH).
2.2.  Animal preparation and supplementation with 
n-3 LCPUFA (EPA plus DHA)
Weaning male C57BL/6J mice weighing 12 to 
14 g were obtained from the Animal Facility at the 
Faculty of Medicine, University of Chile, Santiago, 
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Chile. Room temperature was kept constant at 
21 °C and light was maintained on a 12:12-h light-
dark cycle. At 20 days of age, mice were randomly 
divided into two diet groups: i) the control diet 
containing (wt/wt) 10% fat, 20% protein, and 70% 
 carbohydrate or ii) a high-fat diet (HFD) containing 
(wt/wt) 60% fat, 20% protein, and 20% carbohydrate 
(D12492, Research Diets, NJ, USA) from days 1 to 
84 (12 weeks). 60% of the fat in the HFD was pro-
vided by the addition of lard (saturated fatty acids 
and cholesterol) in significantly higher amounts 
compared to the control diet. After 12 weeks, the 
animals given the control diet were divided into 
two diet groups (n=9): a) control diet, b) control 
diet plus n-3 LCPUFA; similarly, the animals sub-
jected to the HFD were divided into two diet groups 
(n=9):  c) change to control diet and d) change to 
control diet plus n-3 LCPUFA; all groups  continued 
during 8 weeks to complete 20 weeks of total treat-
ment. The n-3 LCPUFA supplemented groups 
received fish oil (encapsulated fish oil containing 
200 mg·kg–1 [108 mg·kg–1 of  EPA and 92 mg·kg–1 
of  DHA]; Acolest) through oral administration; the 
control groups were given iso-volumetric amounts 
of saline. Weekly controls of  body weight and diet 
intake were carried out throughout the entire period. 
At the end of the 20th week, the animals were fasted 
(6–8 h) and then given an anesthesia with tiletamine 
and zolacepam (Zoletil®, Virbac Laboratories). 
The visceral adipose tissue was extracted from the 
 epididymal area, weighed and stored at −20 °C.
2.3. Tissue and blood samples
Liver samples were frozen in liquid nitrogen and 
stored at −80 °C, or fixed in phosphate-buffered 
formalin, embedded in paraffin, sectioned using a 
microtome and stained with haematoxylin-eosin. 
Blood samples were taken from a cardiac puncture, 
and then centrifuged, and the serum was stored at 
−20 °C. Liver slides were stained with haematox-
ylin-eosin (HE) assessed by optical microscopy 
(Olympus CX31, Japan) for morphology analysis in 
a blind fashion. The presence of both steatosis and 
inflammation were graded as absent, mild,  moderate 
or severe (Brunt et al., 1999).
2.4. Western blot analysis of CAT-1 and AP-1
Liver samples (100–500 mg) frozen in liquid 
nitrogen were homogenized and suspended in a 
buffer solution pH 7,9 containing 10mM HEPES, 
1mM EDTA, 0,6% Nonidet p-40, 150mM NaCl 
and protease inhibitors (1mM phenylmethylsulfonyl 
fluoride, 1 μg·mL–1 aprotinin, 1 μg·mL–1 leupeptin, 
and 1mM orthovanadate). Soluble protein fractions 
(10 mg) were separated on 12% polyacrylamide gel 
electrophoresis using SDS-PAGE, transferred to 
nitrocellulose membranes, and blocked with TBS 
containing 5% non-fat dry milk for 1 h at room 
temperature. The blots were washed with TBS-
containing 0.1% Tween 20 and hybridized with 
rabbit polyclonal antibodies for human CAT-1 
(Santa Cruz Biotechnology, CA, USA) and anti-
(c-Jun) (Fitzgerald Industries International, Acton, 
MA, U.S.A.). Mouse monoclonal antibody for rat 
β-actin (ICN Biomedicals, Inc., Aurora, OH) was 
used as internal control in all determinations. After 
extensive washing, the antigen-antibody complexes 
were detected using labeled horseradish peroxidasa, 
and a Super Signal West Pico Chemiluminescence 
kit detection system (Pierce, Rockford, IL, USA).
2.5. RT-PCR assay of ACOX mRNA expression
The expression of ACOX was assessed by 
RT-PCR. Total RNA was isolated from 15–25 mg 
of frozen liver using an E.Z.N.A. total RNA Kit 
(Omega Biotek, Norcross, Georgia, USA) according 
to the manufacturer’s instructions. Quantification of 
total RNA was performed spectrophotometrically 
(A260/A280 ratio) and RNA quality was checked by 
electrophoresis on 1.2% agarose gels, using a molec-
ular size marker. The resulting DNAse free RNA 
was reverse-transcribed to cDNA with a Thermo 
Script reverse transcriptase (Invitrogen Corp., 
Carlsbad, CA, USA) according to the manufac-
turer’s instructions using random hexamer  primers 
(Promega, Madison, WI, USA). The resulting 
cDNA was amplified in a PCR reaction using Taq 
DNA polymerase recombinant (Invitrogen Corp., 
Carlsbad, CA, USA), according to the manufac-
turer’s instructions. Nucleotide sequences for sense 
and antisense primers used in this study were (Fwd: 
5`-ACCTTCAGGCCCAAGTGAGT-3` and Rv : 5`
-GAGCCCCTGTGATGATGTTC-3`) and the con-
trol 18S rRNA as internal control (Quantum RNA 
18S Internal Standards, Ambion Inc., Austin TX, 
EE.UU). The amplification (TECHNE TC-5000, 
Bibby Scientific Ltd., United Kingdom) was initi-
ated after 5 min de-naturation at 94 °C, followed 
by 34 cycles (94 °C for 30s, 62 °C for 30 s, 72  °C 
for 30 s) and finalizing with 72 °C for 5 min. The 
expected outputs for each amplification correspond 
to 249 pb for ACOX. All amplification products 
were stored at 4 °C. PCR products were electro-
phoresed on 1.2% agarose gels containing ethidium 
bromide,  visualized by UV-induced fluorescence, 
and  analyzed for densitometry using UN-SCAN-IT 
software (Silk Scientific Inc., Orem, UT, USA).
2.6. Immunohistochemistry studies
For AP-1 staining a specific antibody was used 
against the c-jun subunit followed by deparaffina-
tion and rehydration. The sections were then incu-
bated with EDTA for 45 minutes at 95 °C. Then, 
blocking was carried out for 30 minutes followed 
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by incubation with primary antibody anti-(c-jun) 
(Fitzgerald Industries International, Acton, MA, 
U.S.A) according to the manufacturer’s instruction. 
For nuclear contrast the Hematoxilin of Mayer was 
used (Modified solution according to Lillie, ScyTek 
Laboratories, Utah, USA). An analysis of posi-
tive nuclei was performed under light microscope 
in a blind fashion in 10 adjacent (400×) per slide. 
Then a percentage of positive nuclei per slide was 
calculated.
2.7. Statistical analyses
Statistical analysis was performed with GraphPad 
PrismTM version 5.0 (GraphPad Software, Inc. San 
Diego, CA, USA). Values shown represent the mean 
± SEM for the number of separate experiments indi-
cated. One-way ANOVA and the  Newman-Keuls 
test for unpaired data assessed the statistical sig-
nificance of differences between mean values as 
 indicated, considering P<0.05 as significant.
3. RESULTS
3.1.  Reduction in adipose tissue weight and corporal 
weight ratio, liver steatosis and morphological 
alterations induced by a HFD with change to the 
control diet with n-3 LCPUFA supplementation
The weights of the animals subjected to the con-
trol diet or HFD with and without n-3 LCPUFA 
supplementation were not significantly different. 
However, the visceral adipose tissue/body weight 
ratio was enhanced (P<0.05) in the mice subjected 
to HFD+CD compared with CD+CD, CD+ 
CD/n-3 LCPUFA, and HFD+CD/n-3 LCPUFA 
(Fig. 1A). In all groups, liver histology was char-
acterized by the absence of architectural distor-
tion, lobular inflammation, necrotic foci, or fibrosis 
(Fig. 1B), and those given CD with and without n-3 
LCPUFA did not show lipid infiltration [Fig. 1B, 
(a) and (b)]. However, HFD+CD exhibited macro 
and  micro-vesicular steatosis (30% lipid vesicles 
infiltration) (Fig. 1B (c)), whereas HFD+CD/n-3 
LCPUFA elicited 8% fat infiltration (Fig. 1B (d); 
Fig. 1C; P<0.05).
3.2.  Change to control diet with n-3 LCPUFA 
supplementation reduces the liver expression 
of enzymes involved in fatty oxidation
Measurement of the enzymes involved in fatty liver 
oxidation CAT-1 and ACOX (Fig. 2) showed that 
mice subjected to the change from HFD to CD had 
lower expressions in their mRNA (ACOX, Fig. 2A) 
and protein levels (CAT-1) (Fig. 2B) with respect to 
the CD group (P<0.05), whereas the change from 
HFD to CD/n-3 LCPUFA increased the expression 
of these enzymes to control values (Fig. 2A y B).
3.3.  Change to control diet with n-3 LCPUFA 
supplementation normalizes the AP-1 levels.
The presence of liver AP-1 in nuclear  fractions, 
assessed by immunohistochemistry, (Fig. 3A), revealed 
that the mice subjected to CD+CD and CD+CD/n-3 
LCPUFA exhibited a percentage of 36.53% and 
33.13% of c-jun liver positive nuclei, respectively; 
whereas animals given HFD+CD showed 63.30% 
(P<0.05). The HFD+CD/n-3 LCPUFA group shows 
a diminished c-jun liver positive nuclei (P<0.05) with 
respect to HFD+CD group, with a 44.30% of c-jun 
liver positive nuclei (Fig. 3B). However, when ana-
lyzed by western blot, there were no significant differ-
ences at the c-jun  protein level among all the groups 
(Fig. 3C).
4. DISCUSSION
NAFLD is a condition that requires multiple 
 factors for development (Adams et  al., 2005), 
which are induced by excessive carbohydrate or 
lipid dietary ingestion (Leamy et  al., 2013). Once 
this condition is acquired, it is important to slow 
its progress to steatohepatitis; later the condition is 
essentially  irreversible (Dowman et al., 2010).
Mice with the HFD intake developed glucose 
intolerance and insulin resistance, with higher 
 visceral adiposity and hepatic steatosis when com-
pared with animals subjected to a norm caloric 
diet (Dossi et al., 2014). Previously published data 
show that a norm caloric diet plus n-3 LCPUFA 
supplementation reverses the HFD-induced pro-
steatotic and pro-inflammatory state in mice liv-
ers. This reversal was evidenced by a reduction in 
insulin resistance, suppression of liver oxidative 
stress and inflammatory cytokine expression (IL-
1β and TNF-α). These findings were associated 
with major changes in hepatic nuclear abundance 
of the lipid metabolism-related transcription fac-
tors PPAR-α and SREBP-1c, with abolishment 
of the  HFD-induced enhancement in SREBP-1c/
PPAR-α ratios by combined HFD and n-3 LCPUFA 
 supplementation. This situation favors catabolism 
over anabolism and that effect could be mediated 
by SREBP-1c and PPAR-α (Dossi et  al., 2014). 
This view is supported by the significant correlation 
between the reduction observed in the hepatic levels 
of the PPAR-α-regulate enzymes ACOX and CAT-1 
(Figure 2A y 2B). From a mechanistic point of view, 
down- regulation of liver enzymes ACOX and CAT-1 
may be ascribed to hepatic n-3 LCPUFA depletion 
(Araya et  al., 2004; Araya et  al., 2010; Valenzuela 
et  al., 2012) observed in experimental and human 
obesity. Different PPAR-α agonist factors are able to 
lower the number of available triglycerides through 
different pathways (Araya et al., 2004; Surwit et al., 
1988). In this respect, here we observed a significant 
increase in both mRNA ACOX levels and CAT-1 
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FIGURE 1. Effect of  n-3 long-chain polyunsaturated fatty acid (n-3 LCPUFA) and dietary change on (A) relation between weight 
of  visceral adipose tissue (g) and corporal weight (g), (B) liver histology (magnification×100) and (C) hepatocyte lipid infiltration 
in mice. Animals were given either (a) control diet (CD), (b) CD plus n-3 LCPUFA (CD+CD/n-3 LCPUFA), (c) high fat diet 
(HFD) followed by CD (HFD+CD), or (d) HFD plus CD supplemented with  n-3 LCPUFA (HFD+CD/n-3 LCPUFA). Values are 
expressed as mean±SEM for 9 animals per experimental group. Letters above the bars indicate statistically significant differences 
(P<0.05) compared to the respective animals given the control diet assessed by one-way ANOVA and the Newman-Keuls.
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protein levels in those animals that underwent the 
norm caloric diet change and supplementation with 
n-3 LCPUFA.
The effects of n-3 LCPUFA could be due to  several 
molecular mechanisms. These include a decrease in 
fatty acids and glycerol mobilization from periph-
eral tissue lipolisis to the liver (Valenzuela et  al., 
2012). In addition, n-3 LCPUFA enhances the anti-
oxidant potential of the liver, acting through direct 
(ROS scavenging) and/or indirect (nuclear tran-
scription factor erythroid 2 related factor 2 (Nrf2) 
activation) mechanisms, a condition proposed to 
improve insulin sensitivity (De Leijer et  al., 2010; 
Fernández-Sanchez et  al., 2011). Alternatively, 
the n-3 LCPUFA metabolism generates various 
potent anti-inflammatory mediators including: i) 
E-series and D-series of resolvins produced by the 
action of cyclooxygenase-2 (COX-2) and 5-lipoxy-
genase (5-LOX) (Michalik et al., 2006), ii) 5-LOX-
dependent protectin D1 production (Videla et  al., 
2012) and iii) formation of epoxyeicosaquatrae-
noic acid and epoxydocosapentaenoic acid cata-
lyzed by cytochrome P450 NADPH-dependent 
 epoxygenases (Houstis et  al., 2006). n-3 LCPUFA 
effects on liver fibrosis and inflammation are 
being currently addressed by several clinical trials 
(De Roos et al., 2009).
Previous studies showed that these metabolic 
alterations decrease when changed to a norm 
caloric diet (Dossi et al., 2014; Surwit et al., 1988; 
De Meijer et  al., 2010), whereas n-3 LCPUFA 
supplementation prevented an HFD-induced 
increase in liver lipid  content (Nobili et  al., 2012; 
Valenzuela et  al., 2012). The increase in visceral 
adipose tissue content induced by the HFD pro-
duces an increment in the pro- inflammatory cyto-
kine (adipokines) secretion such as IL-6, IL-1β and 
TNF-α (Fernández-Sánchez et  al., 2011). In this 
respect, the significant increase in the visceral adi-
pose tissue/corporal body weight ratio and hepatic 
lipid infiltration in the the HFD+CD group was 
normalized in the HFD+CD/n-3 LCPUFA group, 
meaning that n-3 LCPUFAS are involved in lipid 
content changes and thus could be also involved in 
the cytokine expression decrease. The decrease in the 
cytokine expression could be explained by the reduc-
tion in the nuclear c-jun content. Previous studies 
support the participation of c-jun (as a subunit of 
AP-1) in developing NAFLD, supporting the results 
found in this study (Dorn et al., 2014). The increase 
in AP-1 expression could be in part responsible for 
the pro-inflammatory cytokine (IL-1β and TNF-α) 
expression observed in HFD (Dossi et al., 2014). It 
has been observed that increasing c-jun, and there-
fore AP-1, leads to an increased transcription of the 
c-jun, in an auto-regulatory cycle, indicating that the 
c-jun increase in NAFLD is a consistent indicator of 
the AP-1 dimmer increase, and it could participate 
in increasing the transcription of pro-inflammatory 
cytokines, which are elevated in the development of 
this  pathology (Hasenfuss et  al., 2014). In another 
aspect, the action of AP-1 factor has been linked with 
the sensor lipid PPAR, postulating an inhibitory role 
to the AP-1 factor, acting in the PPAR-DNA bind-
ing (Ye et  al., 2002); thus, performing a protective 
role. In mice with HFD-induced hepatic steatosis an 
upregulation of PPAR-γ levels was evident (Shapiro 
et al., 2011) and is regulated differently depending on 
the AP-1 dimer formed: c-jun joined Fra-1 and Fra-2 
(members of the Fos family) inhibit the expression 
of PPAR-γ resulting in a liver steatotic reduction, 
but the dimmer formed by c-jun and c-Fos has the 
opposite effect (Fernández-Sanchez et al., 2011).
To increase the reliability of the results obtained 
in this work, we analyzed the subunit c-jun levels 
using two techniques based on the antigen-antibody 
union: immunohistochemistry and western  blotting; 
both techniques aim to determinate the relative levels 
of the protein. The immunohistochemical analysis 
allowed for determination of the AP-1 levels through 
the measurement of the subunit c-jun (Halazonetis 
et al., 1988; Hong et al., 2003). The analysis showed 
that dietary change associated with n-3 LCPUFA 
supplementation is effective in reducing AP-1 levels, 
although it does not show significant differences in 
the measurement by western blot. Regarding the dif-
ferences obtained with both techniques, it is impor-
tant to mention that tissue processing is a relevant 
factor in the discrepancy found in the results of each 
technique. Immunohistochemistry is set to maintain 
FIGURE 2. Effect of n-3 long-chain polyunsaturated fatty 
acid (n-3 LCPUFA) and dietary change on expression of 
liver enzymes Acyl coenzyme A oxidase (ACOX) mRNA 
levels (A) and Carnitina acyl transferase 1 (CAT-1) (Western 
blot). Animals were given either (a) control diet (CD), (b) CD 
plus n-3 LCPUFA (CD+CD/n-3 LCPUFA), (c) high fat diet 
(HFD) followed by CD (HFD+CD), or (d) HFD plus CD 
supplemented with n-3 LCPUFA (HFD+CD/n-3 LCPUFA). 
Values are expressed as mean±SEM for 9 animals per 
experimental group. Letters above the bars indicate statistically 
significant differences (P<0.05; one-way ANOVA and the 
Newman-Keuls, test).
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the morphology of the living body, which involves 
maintaining the three dimensional structure of 
protein; while in the western blotting, the tissue is 
homogenized and then treated with de-naturating 
agents such as SDS (sodium dodecyl sulfate) and 
β-mercaptoethanol, causing a loss of the three-
dimensionality of proteins, which could directly 
affect the antigen-antibody binding agents. The loss 
of the tertiary structure of c-jun may be the reason 
for the differences in the results between the  two 
techniques as antibody binding can occur in the dif-
ferent structures that make up a protein ( primary, 
secondary, tertiary or quaternary).
Considering these results together, we conclude 
that n-3 LCPUFA supplementation associated with 
diet change reverses the HFD-induced hepatic ste-
atosis, along with a recovery of ACOX and CAT-1 
levels and normalization of the AP-1 nuclear sub-
unit c-jun levels.
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FIGURE 3. Effect of n-3 long-chain polyunsaturated fatty acid (n-3 LCPUFA) and dietary change on (A) immunohistochemical 
determination of c-jun nuclear, (B) percentage of positive nuclei for c-jun, and (C) densitometric units of c-jun (Western blot) in 
mice. Animals were given either (a) control diet (CD), (b) CD plus n-3 LCPUFA (CD+CD/n-3 LCPUFA), (c) high fat diet (HFD) 
followed by CD (HFD+CD), or (d) HFD plus CD supplemented with n-3 LCPUFA (HFD+CD/n-3 LCPUFA). Values are expressed 
as mean±SEM for 9 animals per experimental group. Letters above the bars indicate statistically significant differences (P<0.05; 
one-way ANOVA and the Newman-Keuls test).
a b c d
0
20
40
60
80
a,b,d
Li
ve
r n
uc
le
ar
 c
-ju
n
(%
 po
sit
ive
 nu
cle
i)
c-jun
β-Actina
a         b            c           d   
a b c d
0.0
0.2
0.4
0.6
D
en
s
ito
m
e
tri
cs
 
Un
its
(c-
Ju
n/
Ac
tin
a)
(A)
(B)
(C)
a
b
c
d
8 • G.S. Tapia, D. González-Mañán, A. D’Espessailles and C.G. Dossi
Grasas Aceites 67 (2), April–June 2016, e134. ISSN-L: 0017-3495 doi: http://dx.doi.org/10.3989/gya.0886152
REFERENCES
Adams LA, Angulo P and Lindor KD. 2005. Nonalcoholic 
fatty liver disease. Can. Med. Assoc. J. 172, 899–905. http://
dx.doi.org/10.1503/cmaj.045232.
Angel P, Hattori K, Smeal T and Karin M. 1988. The jun 
proto-oncogene is positively autoregulated by its prod-
uct, jun/AP-1. Cell. 55, 875–885. http://dx.doi.org/10. 
1016/0092-8674(88)90143-2.
Araya J, Rodrigo R, Pettinelli P, Araya V, Poniachik J and Videla 
L. 2010. Decreased liver fatty acid ∆-6 and ∆-5 desaturase 
activity in obese patients. Obesity. 18, 1460–1463. http://
dx.doi.org/10.1038/oby.2009.379.
Araya J, Rodrigo R, Videla L, Thielemann L, Orellana M, 
Pettinelli P and Poniachik J. 2004. Increase in long-chain 
polyunsaturated fatty acid n-6/n-3 ratio in relation to 
hepatic steatosis in patients with non-alcoholic fatty liver 
disease. Clin. Sci. 106, 635–643. http://dx.doi.org/10.1042/
cs20030326.
Aronis A, Madar Z and Tirosh O. 2005. Mechanism underlying 
oxidative stress-mediated lipotoxicity: Exposure of J774.2 
to macrophages triacylglycerols facilitates mitochondrial 
reactive oxygen species production and cellular necro-
sis. Free Radic. Biol. Med. 38, 1221–1230. http://dx.doi.
org/10.1016/j.freeradbiomed.2005.01.015.
Baffy G. 2009. Kupffer cells in non-alcoholic fatty liver disease: 
The emerging view. J. Hepatol. 51, 212–223. http://dx.doi.
org/10.1016/j.jhep.2009.03.008.
Bartlett K and Eaton S. 2004. Mitochondrial β-oxidation. 
Eur. J. Biochem. 271, 462–469. http://dx.doi.org/10.1046/j. 
1432-1033.2003.03947.x.
Bellentani S, Scaglioni F, Marino M and Bedogni G. 2010. 
Epidemiology of non-alcoholic fatty liver disease 
(NAFLD). Dig Dis. 28, 155–161. http://dx.doi.org/10. 
1159/000282080.
Brunt EM, Janney CG, Di Biscegle AM, Neuschwander-Tetri 
BA and Bacon BR. 1999. Nonalcoholic steatohepati-
tis: a proposal for grading and staging the histological 
lesions. Am. J. Gastroenterol. 94, 2467–2474. http://dx.doi.
org/10.1111/j.1572-0241.1999.01377.x.
Delerive P, Fruchart JC and Staels B. 2001. Peroxisome 
proliferator-activated receptors ininflamation control. 
J. Endocrinology. 169, 453–459. http://dx.doi.org/10.1677/
joe.0.1690453. 
De Roos B, Mavrommatis Y and Brouwer I. 2009. Long-
chain n-3 polyunsaturated fatty acids: new insights into 
mechanisms relating to inflammation and coronary heart 
disease. Br. J. Pharmacol. 158, 413–428. http://dx.doi.
org/10.1111/j.1476-5381.2009.00189.x. 
De Meijer V, Le H, Meisel J, Sharif  M, Pan A, Nosé V 
and Puder M. 2010. Dietary fat intake promotes 
the development of  hepatic steatosis independently 
from excess caloric consumption in a murine model. 
Metabolism. 59, 1092–105. http://dx.doi.org/10.1016/j.
metabol.2009.11.006. 
Dorn C, Engelmann J, Saugspier M, Koch A, Hartmann A, 
Müller M, Spang R, Bossenhorff  A and Hellerbrand 
C. 2014. Increased expression of c-Jun in nonalcoholic 
fatty liver disease. Lab Invest. 94, 394–408. http://dx.doi.
org/10.1038/labinvest.2014.3.
Dossi CG, Tapia GS, Espinosa A, Videla LA and D’Espessailles 
A. 2014. Reversal of High-fat diet-induced hepatic ste-
atosis by n-3 LCPUFA: role of PPAR-α and SREBP-1c. 
J. Nutr. Biochem. 25, 977–984. http://dx.doi.org/10.1016/j.
jnutbio.2014.04.011.
Dowman JK, Tomlinson JW and Newsome PN. 2010. 
Pathogenesis of non-alcoholic fatty liver disease. Int. J. Med. 
103, 71–83. http://dx.doi.org/10.1093/qjmed/hcp158.
Fernandez-Sanchez A, Madrigal-Santillan E, Bautista M, 
Esquivel-Soto J, Morales-Gonzalez A, and Esquivel-
Chirino C. 2011. Inflammation, Oxidative Stress, and 
Obesity. Int J Mol Sci. 12, 3117–32. http://dx.doi.org/ 
10.3390/ijms12053117.
Hasenfuss SC, Bakiri L, Thomsen M, Williams E, Auwerx J and 
Wagner E. 2014. Regulation of Steatohepatitis and PPARγ 
Signaling by Distinct AP-1 Dimers. Cell Metabolism. 19, 
84–95. http://dx.doi.org/10.1016/j.cmet.2013.11.018. 
Hong S, Gronert K, Devchand PR, Moussignac RL and Serhan 
CN. 2003. Novel docosatrienes and 17S-resolvins gener-
ated from docosahexaenoic acid in murine brain, human 
blood, and glial cells: Autacoids in anti-inflammation. 
J. Biol. Chem. 278, 14677–14687. http://dx.doi.org/10.1074/
jbc.m300218200.
Houstis N, Rosen E and Lander E. 2006. Reactive oxygen spe-
cies have a causal role in multiple forms of insulin resis-
tance. Nature 440, 944–948. http://dx.doi.org/10.1038/
nature04634.
Inoue M, Ohtake T, Motomura W, Takahashi N, Hosoki Y, 
Miyoshi S, Suzuki Y, Saito H, Kohgo Y and Okumura T. 
2005. Increased expression of PPARγ in high fat diet-
induced liver steatosis in mice. Bioch and Bioph Res Comms. 
336, 215–222. http://dx.doi.org/10.1016/j.bbrc.2005.08.070. 
Leamy AK, Egnatchik RA and Young JD. 2013. Molecular 
Mechanisms and the Role of Saturated Fatty Acids in 
the Progression of Non-Alcoholic Fatty Liver Disease. 
Prog Lipid Res. 52:165–174. http://dx.doi.org/10.1016/j.
plipres.2012.10.004.
Malaguarnera M, Di Rosa M, Nicoletti F, Malaguarnera L. 
2009. Molecular mechanisms involved in NAFLD progres-
sion. J. Mol. Med. 87, 679–695. http://dx.doi.org/10.1007/
s00109-009-0464-1.
Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass 
CK, Gonzalez FJ, et  al. 2006. International Union of 
Pharmacology. LXI. Peroxisome Proliferator-Activated 
Receptors. Pharmacol Rev. 58, 726–741. http://dx.doi.
org/10.1124/pr.58.4.5.
Musso G, Gambino G, and Cassader M. 2009. Recent insights 
into hepatic  lipid metabolism in non-alcoholic fatty liver 
disease (NAFLD). Prog. in Lipid Research. 48, 1–26. http://
dx.doi.org/10.1016/j.plipres.2008.08.001.
Nobili V and Sanyal AJ. 2012. Treatment of nonalcoholic 
fatty liver disease in adults and children: closer look at 
the  arsenal. J. Gastroenterol. 47, 29–36. http://dx.doi.
org/10.1007/s00535-011-0467-x.
Poirier Y, Antonenkov VD, Glumoff T and Hiltunen JK. 2006. 
Peroxisomal β-oxidation: A metabolic pathway with mul-
tiple functions. Mol Cell Res. 1763, 1413–1426. http://
dx.doi.org/10.1016/j.bbamcr.2006.08.034.
Shapiro H, Tehilla M, Attal-Singer J, Bruck R, Luzzatti R 
and Singer P. 2011. The therapeutic potential of long-
chain omega-3 fatty acids in nonalcoholic fatty liver dis-
ease. Clin Nutr. 30, 6–19. http://dx.doi.org/10.1016/j.
clnu.2010.06.001. 
Surwit RS, Kuhn CM, Cochrane C, McCubbin JA and Feinglos 
MN. 1988. Diet-induced type II diabetes in C57BL/6J 
mice. Diabetes. 37, 1163–1167. http://dx.doi.org/10.2337/
diab.37.9.1163.
Thanos D, Georgopoulos K, Greenberg M and Leder P. 1988. 
c-jun dimerizes with itself  and with c-fos, forming com-
plexes of different DNA binding affinities. Cell. 55, 
917–924. http://dx.doi.org/10.1016/0092-8674(88)90147-x.
Valenzuela R and Videla L. 2011. The importance of the 
long-chain polyunsaturated fatty acid n-6/n-3 ratio in 
development of non-alcoholic fatty liver associated with 
obesity. Food Funct. 2, 644–648. http://dx.doi.org/10.1039/
c1fo10133a.
Valenzuela R, Espinosa A, González D, Fernández V, Videla 
LA, Romanque P, et al. 2012. N-3 long-chain polyunsatu-
rated fatty acid supplementation significantly reduces liver 
oxidative stress in high fat induced steatosis. Plos One. 7, 
e46400. http://dx.doi.org/10.1371/journal.pone.0046400.
Videla L and Pettinelli P. 2012. Misregulation of PPAR function-
ing and its pathogenic consequences associated with nonal-
coholic fatty liver disease in human obesity. PPAR Res. 2012, 
1–14. http://dx.doi.org/10.1155/2012/107434.
Ye D, Zhang D, Oltman C, Dellsperger K, Lee HC and Van 
Rollins M. 2002. Cytochrome P-450 epoxygenase metabo-
lites of docosahexaenoate potently dilate coronary arte-
rioles by activating large-conductance calcium-activated 
potassium channels. J. Pharmacol. Exp. Ther. 303, 768–776. 
http://dx.doi.org/10.1124/jpet.303.2.768.
